Edition:
United States

Novartis AG (NOVN.S)

NOVN.S on Virt-X Level 1

81.88CHF
21 Sep 2018
Change (% chg)

CHF-0.06 (-0.07%)
Prev Close
CHF81.94
Open
CHF82.50
Day's High
CHF82.50
Day's Low
CHF81.28
Volume
13,399,681
Avg. Vol
4,411,177
52-wk High
CHF88.30
52-wk Low
CHF71.84

Latest Key Developments (Source: Significant Developments)

Novartis AG Says Faces Impairment Of About Usd70 Million Related To Sale Of Assets To India's Aurobindo, Will Confirm At Q3 Earnings Report On Oct 18
Thursday, 6 Sep 2018 01:29pm EDT 

Novartis Ag ::SAYS FACES IMPAIRMENT OF ABOUT USD70 MILLION RELATED TO SALE OF ASSETS TO INDIA'S AUROBINDO, WILL CONFIRM AT Q3 EARNINGS REPORT ON OCT 18.SAYS FACES IMPAIRMENT OF ABOUT USD70 MILLION RELATED TO SALE OF ASSETS TO INDIA'S AUROBINDO, WILL CONFIRM AT Q3 EARNINGS REPORT ON OCT 18.  Full Article

Aurobindo Pharma Unit To Buy Commercial Ops And 3 Manufacturing Facilities From Sandoz
Wednesday, 5 Sep 2018 10:39pm EDT 

Sept 6 (Reuters) - Aurobindo Pharma Ltd ::UNIT AUROBINDO PHARMA USA ENTERED DEAL TO BUY COMMERCIAL OPERATIONS AND THREE MANUFACTURING FACILITIES IN USA FROM SANDOZ ., USA.DEAL FOR $0.9 BILLION IN CASH ON DEBT FREE AND CASH FREE BASIS INCLUDING POTENTIAL UPSIDE IN NEAR TERM EARN-OUT.DEAL WILL BE AN ALL CASH TRANSACTION WHICH AUROBINDO WILL FINANCE THROUGH A FULLY COMMITTED DEBT FACILITY.  Full Article

Novartis Says To Divest Sandoz U.S. Dermatology Business And Generic U.S. Oral Solids Portfolio To Aurobindo
Wednesday, 5 Sep 2018 10:30pm EDT 

Sept 5 (Reuters) - Novartis AG ::NOVARTIS TO DIVEST SANDOZ US DERMATOLOGY BUSINESS AND GENERIC US ORAL SOLIDS PORTFOLIO TO AUROBINDO.TO FOCUS SANDOZ DIVISION IN US ON HIGHER GROWTH AREAS AND TO SELL SELECTED PORTIONS OF SANDOZ US PORTFOLIO TO AUROBINDO PHARMA USA.AGREEMENT COMPRISES SANDOZ US GENERIC ORAL SOLIDS AND SANDOZ US DERMATOLOGY BUSINESSES.AGREED TO SELL SELECTED PORTIONS OF SANDOZ US PORTFOLIO TO AUROBINDO PHARMA USA FOR $0.9 BILLION OF CASH PLUS $0.1 BILLION OF POTENTIAL EARN-OUTS.SANDOZ US PORTFOLIOS TO BE SOLD TO AUROBINDO INCLUDE APPROXIMATELY 300 PRODUCTS, AS WELL AS ADDITIONAL DEVELOPMENT PROJECTS.  Full Article

Novartis AG CEO Says 'Unprecedented Demand' In U.S. For Migraine Drug Aimovig Bodes Well For Europe
Wednesday, 18 Jul 2018 09:17am EDT 

July 18 (Reuters) - Novartis AG ::CEO SAYS SEES "UNPRECEDENTED DEMAND" IN US FOR MIGRAINE DRUG AIMOVIG, SAYS BODES WELL FOR EUROPE.CEO SAYS LUTATHERA EXCEEDING EXPECTATIONS IN UNITED STATES.CFO SAYS NOVARTIS MAY RAISE GUIDANCE FOR SALES GROWTH IN Q3, STILL TOO EARLY TO MAKE DECISION NOW.SANDOZ GENERICS HEAD SAYS U.S. MARKET GROWING MORE POSITIVE TOWARD BIOSIMILARS.CEO SAYS EXPLORING OPTIONS FOR ADDITIONAL KYMRIAH MANUFACTURING CAPACITY IN ASIA.NOVARTIS AG NOVN.S SANDOZ HEAD SAYS 2018 SALES GUIDANCE DOWNGRADE FOR GENERICS BUSINESS BASED ON RIXATHON DELAY IN U.S., SLOW GLATOPA 40 MG LAUNCH DUE TO PRICING PRESSURE AND SIGNIFICANT DESTOCKING IN RUSSIA IN FIRST HALF OF YEAR.  Full Article

Rovi Signs Distribution Agreement With Sandoz
Tuesday, 12 Jun 2018 06:07am EDT 

June 12 (Reuters) - Rovi ::REACHES AGREEMENT WITH SANDOZ, A UNIT OF NOVARTIS, FOR DISTRIBUTION AND MARKETING OF ITS ENOXAPARIN BIOSIMILAR.GRANTS SANDOZ AN EXCLUSIVE LICENSE TO MARKET PRODUCT IN HONG KONG, SINGAPORE AND VIETNAM.  Full Article

Regenxbio Receives $100 Mln Accelerated License Payment
Monday, 11 Jun 2018 04:05pm EDT 

June 11 (Reuters) - Regenxbio Inc ::REGENXBIO RECEIVES $100 MILLION ACCELERATED LICENSE PAYMENT DUE TO ACQUISITION OF AVEXIS BY NOVARTIS.REGENXBIO - ACCELERATED LICENSE PAYMENT CONSISTED OF $60 MILLION IN ANNUAL FEES AND A COMMERCIAL MILESTONE FEE OF $40 MILLION.REGENXBIO INC - NOVARTIS NOW HOLDS EXCLUSIVE RIGHTS TO NAV TECHNOLOGY PLATFORM FOR DEVELOPMENT OF TREATMENTS FOR SMA.REGENXBIO INC - REGENXBIO REMAINS ELIGIBLE TO RECEIVE A POTENTIAL COMMERCIAL MILESTONE FEE.  Full Article

Novartis Completes Sale Of Stake In Consumer Healthcare JV To GSK
Friday, 1 Jun 2018 08:00am EDT 

June 1 (Reuters) - NOVARTIS AG ::COMPLETES SALE OF STAKE IN CONSUMER HEALTHCARE JOINT VENTURE TO GSK FOR USD13.0 BILLION.  Full Article

Novartis, Amgen Announce FDA Approval Of Aimovig Treatment For Migraine Prevention
Thursday, 17 May 2018 07:11pm EDT 

May 17 (Reuters) - Novartis Ag ::NOVARTIS AND AMGEN ANNOUNCE FDA APPROVAL OF AIMOVIG™ (ERENUMAB-AOOE), A NOVEL TREATMENT DEVELOPED SPECIFICALLY FOR MIGRAINE PREVENTION.EMA MARKETING AUTHORIZATION APPLICATION FOR AIMOVIG IS UNDER REVIEW. NOVARTIS EXPECTS APPROVAL IN EU IN COMING MONTHS.  Full Article

Novartis says set to deliver sales growth, margin expansion through 2022
Wednesday, 16 May 2018 01:21am EDT 

May 16 (Reuters) - Novartis AG ::SAYS POSITIONED TO DELIVER SALES GROWTH AND MARGIN EXPANSION THROUGH 2022.SAYS ALCON RETURNING TO A POSITION OF STRENGTH AS WORLD'S LEADING EYE CARE DEVICES COMPANY.CEO SAYS FIRM MADE MISTAKES RECENTLY AND WORLD RIGHTLY EXPECTS MORE FROM A LEADING HEALTHCARE COMPANY.SAYS DESPITE CONTINUING US PRICING PRESSURE, GLOBALLY, SANDOZ GROSS MARGIN IS IMPROVING.SAYS IN US, SANDOZ IS OPTIMIZING PORTFOLIO THROUGH TARGETED PRUNING AND LEARNING FROM RECENT SETBACKS.SAYS MANAGEMENT HIGHLIGHTS ACTIONS THAT HAVE RETURNED BUSINESS TO GROWTH AND IMPROVED MARGINS.SAYS ALCON STRATEGIC REVIEW IS ON TRACK WITH ACTION NOT EXPECTED BEFORE FIRST HALF OF 2019.SAYS ALCON EXPECTS TO RETURN TO LONG-TERM, SUSTAINABLE GROWTH WITH MARGINS IN LINE WITH INDUSTRY PEERS.  Full Article

Novartis Successfully Completes Acquisition Of Avexis
Tuesday, 15 May 2018 04:00pm EDT 

May 15 (Reuters) - Novartis AG ::NOVARTIS SUCCESSFULLY COMPLETES ACQUISITION OF AVEXIS, INC..  Full Article

BRIEF-Novartis - Positive CHMP Opinion For Sandoz' Biosimilar Pegfilgrastim

* SANDOZ RECEIVES POSITIVE CHMP OPINION FOR PROPOSED BIOSIMILAR PEGFILGRASTIM